[DICER1 constitutional pathogenic variant syndrome: Where are we in 2019?]
Syndrome associé aux variants pathogènes constitutionnels de DICER1 : Où en sommes-nous en 2019 ?
Children
Conseil génétique
DICER1
Dépistage
Enfant
Genetic counseling
Ovarian Sertoli-Leydig tumor
Pleuropneumoblastoma
Pleuropneumoblastomes
Rare tumors
Screening
Surveillance
Tumeur ovarienne de Sertoli-Leydig
Tumeurs rares
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
24
03
2019
revised:
09
08
2019
accepted:
14
08
2019
pubmed:
16
10
2019
medline:
18
12
2019
entrez:
16
10
2019
Statut:
ppublish
Résumé
Inactivating germline pathogenic variants of the DICER1 gene are responsible for a spectrum of rare diseases, which expanded a lot in recent years. The constitution of an U.S. registry with these patients and their families as well as the registration of patients in European databases of rare tumors helped to better identify diseases encountered in this syndrome but also to study its pathophysiology (major role in miRNA maturation and recently discovered functions, e.g. in genome integrity maintenance). Most encountered disorders are pediatric malignancies, mainly the pulmonary pneumoblastoma and Sertoli-Leydig tumours. However, benign pathologies such as thyroid goiters, cystic nephromas or pulmonary cystic lesions are also frequently reported. Homogeneous guidelines regimens written by the European groups working on very rare pediatric tumors are proposed but it is important to underscore that they rely on rare scientific data; therefore overall consensus remains precarious. The genetic counseling to families is still difficult due to the large observed spectrum of tumors and the incomplete penetrance. In this article, the authors update current knowledge on the DICER1 syndrome.
Identifiants
pubmed: 31610911
pii: S0007-4551(19)30332-7
doi: 10.1016/j.bulcan.2019.08.016
pii:
doi:
Substances chimiques
DICER1 protein, human
EC 3.1.26.3
Ribonuclease III
EC 3.1.26.3
DEAD-box RNA Helicases
EC 3.6.4.13
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
1177-1189Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.